FDA Accepts New Drug Application for NEBIDOR Submitted by Indevus Pharmaceuticals, Inc
FDA Accepts New Drug Application for NEBIDOR Submitted by Indevus Pharmaceuticals, Inc There were no major adverse cardiovascular events in the testosterone group, but there were 28 nonfatal strokes and 25 nonfatal myocardial infractions in the control group. Prostate volume increased slightly in the testosterone group, but not to any clinically meaningful degree, and stayed …
FDA Accepts New Drug Application for NEBIDOR Submitted by Indevus Pharmaceuticals, Inc Read More »